查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1722507

2025 年至 2033 年发作性睡病药物市场报告（按类型、疾病类型、治疗类型和地区划分）

Narcolepsy Drugs Market Report by Type, Disease Type, Therapeutic Type, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球嗜睡症药物市场规模达 35 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 65 亿美元，2025-2033 年期间的成长率 (CAGR) 为 6.64%。人们对嗜睡症的认识和诊断不断提高、睡眠障碍的盛行率不断上升、药物开发的不断进步以及有利的监管环境是推动市场成长的主要因素。

嗜睡症药物是指用于治疗慢性睡眠障碍的药物。这种疾病的特征是白天过度嗜睡 (EDS)、猝倒或肌肉力量突然丧失、睡眠瘫痪、幻觉、睡眠片段化和失眠。其他症状可能包括无意识的自动行为、视力模糊、复视或眼睑下垂以及精神功能失调。患有嗜睡症的患者每天的睡眠时间与正常人相同；但睡眠品质往往较差。一些常用的治疗嗜睡症的药物包括中枢神经系统兴奋剂、羟基丁酸钠、选择性血清素再摄取抑制剂和三环抗忧郁剂。这些药物有助于提高成年患者的觉醒程度，并减少幻觉、嗜睡和猝倒症。

嗜睡症药物市场趋势：

全球嗜睡症盛行率的不断上升是推动市场成长的关键因素之一。这可以归因于工作人群久坐的生活方式和忙碌的日程安排，这反过来又大大增加了睡眠相关疾病的发生率。此外，群众健康意识的不断增强以及对可用治疗替代方案的认识不断提高，为市场成长提供了动力。同时，羟基丁酸钠在儿童嗜睡症治疗的广泛应用也促进了市场的成长。此外，嗜睡症诊断技术的显着进步也起到了促进作用。製药商也在开发具有长期效益和减少副作用的药物。其他因素，包括老年人口的增加（老年人更容易患此类疾病）以及神经病学领域的广泛研究和发展 (R&D) 活动，预计将推动市场成长。

本报告回答的关键问题

  • 嗜睡症药物市场有多大？嗜睡症药物市场的未来前景如何？
  • 推动嗜睡症药物市场发展的关键因素有哪些？
  • 哪个地区占据嗜睡症药物最大的市占率？
  • 全球嗜睡症药物市场领先的公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球嗜睡症药物市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 伴随猝倒症的嗜睡症
  • 无猝倒症的发作性睡病
  • 继发性嗜睡症

第七章：市场区隔：依疾病类型

  • 白天极度嗜睡
  • 猝倒症
  • 其他的

第八章：市场区隔：依治疗类型

  • 羟基丁酸钠
  • 中枢神经系统兴奋剂
  • 三环抗忧郁药
  • 选择性血清素再摄取抑制剂
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第十章：SWOT分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Avadel Pharmaceuticals plc
    • Axsome Therapeutics Inc.
    • Bioprojet Pharma
    • Graymark Healthcare Inc.
    • Jazz Pharmaceuticals plc
    • Ligand Pharmaceuticals Incorporated
    • Novartis AG
    • SHIONOGI & Co. Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A5685

The global narcolepsy drugs market size reached USD 3.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.5 Billion by 2033, exhibiting a growth rate (CAGR) of 6.64% during 2025-2033. The increasing awareness and diagnosis of narcolepsy, growing prevalence of sleep disorders, ongoing advancements in drug development, and favorable regulatory environment are primarily driving the market's growth.

Narcolepsy drugs refer to pharmaceutical medicines used for the treatment of chronic sleep disorders. The disorder is characterized by excessive daytime sleepiness (EDS), cataplexy or sudden loss of muscle strength, sleep paralysis, hallucinations, fragmented sleep and insomnia. Additional symptoms may include automatic behaviors without conscious awareness, blurred vision, double vision or droopy eyelids and disturbed mental functioning. Patients suffering from narcolepsy tend to sleep the same number of hours per day as normal individuals; however, sleep quality tends to be poorer. Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants. These drugs aid in improving wakefulness in adult patients and minimizing hallucinations, sleepiness and cataplexy.

Narcolepsy Drugs Market Trends:

The increasing prevalence of narcolepsy across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the working population, which, in turn, is significantly increasing the incidences of sleep-related disorders. Moreover, rising health consciousness among the masses and the increasing awareness regarding the available treatment alternatives are providing a thrust to the market growth. In line with this, the widespread adoption of sodium oxybate for the treatment of narcolepsy in children is also contributing to the growth of the market. Additionally, significant improvements in the diagnostic technologies for narcolepsy are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing variants with long-term benefits and reduced side effects. Other factors, including the rising geriatric population, which is more susceptible to such ailments, along with extensive research and development (R&D) activities in the field of neurology, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Type:

  • Narcolepsy with Cataplexy
  • Narcolepsy without Cataplexy
  • Secondary Narcolepsy

Breakup by Disease Type:

  • Daytime Extreme Sleepiness
  • Cataplexia
  • Others

Breakup by Therapeutic Type:

  • Sodium Oxybate
  • Central Nervous System Stimulants
  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitor
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Bioprojet Pharma, Graymark Healthcare Inc., Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis AG, SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the narcolepsy drugs market?
  • 2.What is the future outlook of narcolepsy drugs market?
  • 3.What are the key factors driving the narcolepsy drugs market?
  • 4.Which region accounts for the largest narcolepsy drugs market share?
  • 5.Which are the leading companies in the global narcolepsy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Narcolepsy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Narcolepsy with Cataplexy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Narcolepsy without Cataplexy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Secondary Narcolepsy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Daytime Extreme Sleepiness
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cataplexia
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Therapeutic Type

  • 8.1 Sodium Oxybate
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Central Nervous System Stimulants
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Tricyclic Antidepressants
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Selective Serotonin Reuptake Inhibitor
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Avadel Pharmaceuticals plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Axsome Therapeutics Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Bioprojet Pharma
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Graymark Healthcare Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Jazz Pharmaceuticals plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Ligand Pharmaceuticals Incorporated
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 SHIONOGI & Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Narcolepsy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Narcolepsy Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Narcolepsy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Narcolepsy Drugs Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Narcolepsy Drugs Market: Breakup by Disease Type (in %), 2024
  • Figure 6: Global: Narcolepsy Drugs Market: Breakup by Therapeutic Type (in %), 2024
  • Figure 7: Global: Narcolepsy Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Narcolepsy Drugs (Narcolepsy with Cataplexy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Narcolepsy Drugs (Narcolepsy with Cataplexy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Narcolepsy Drugs (Narcolepsy without Cataplexy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Narcolepsy Drugs (Narcolepsy without Cataplexy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Narcolepsy Drugs (Secondary Narcolepsy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Narcolepsy Drugs (Secondary Narcolepsy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Narcolepsy Drugs (Daytime Extreme Sleepiness) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Narcolepsy Drugs (Daytime Extreme Sleepiness) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Narcolepsy Drugs (Cataplexia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Narcolepsy Drugs (Cataplexia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Narcolepsy Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Narcolepsy Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Narcolepsy Drugs (Sodium Oxybate) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Narcolepsy Drugs (Sodium Oxybate) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Narcolepsy Drugs (Central Nervous System Stimulants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Narcolepsy Drugs (Central Nervous System Stimulants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Narcolepsy Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Narcolepsy Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Narcolepsy Drugs (Selective Serotonin Reuptake Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Narcolepsy Drugs (Selective Serotonin Reuptake Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Narcolepsy Drugs (Other Therapeutic Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Narcolepsy Drugs (Other Therapeutic Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Narcolepsy Drugs Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Narcolepsy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Narcolepsy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Narcolepsy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Narcolepsy Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Narcolepsy Drugs Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Narcolepsy Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 4: Global: Narcolepsy Drugs Market Forecast: Breakup by Therapeutic Type (in Million USD), 2025-2033
  • Table 5: Global: Narcolepsy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Narcolepsy Drugs Market: Competitive Structure
  • Table 7: Global: Narcolepsy Drugs Market: Key Players